FORE Biotherapeutics has closed an upsized Series D-2 extension financing round, raising $67.4 million to bring the total Series D-2 amount to $110 million. This follow-on round was co-led by SR One, Medicxi, and SymBiosis, with participation from new investors like TaiAx and LG Technology Ventures. The funds will support the company's development of targeted cancer therapies, though specific pipeline or operational metrics were not disclosed.